Background.<\/strong> Postoperative infections remain a significant cause of morbidity in abdominal surgery, especially in clean-contaminated and contaminated procedures. Third-generation cephalosporins have long been used for surgical prophylaxis because of their broad antimicrobial spectrum and favorable pharmacokinetics. Ceftazidime is notable for its intense activity against Pseudomonas aeruginosa<\/em>, a relevant pathogen in nosocomial infections. However, earlier clinical experiences were often based on prolonged prophylaxis, whereas current international guidelines (CDC, WHO, ESCMID) recommend limiting prophylaxis to \u226424 hours, requiring a contextual reinterpretation of historical data.<\/p>\n Methods.<\/strong> A retrospective analysis was performed on 409 patients undergoing elective abdominal surgery between January 2020 and December 2024. Procedures included gallbladder (n = 192), colorectal (n = 115), gastric (n = 56), and uterine surgery (n = 46). Approximately half of the patients received perioperative intravenous ceftazidime, while the remainder were treated with alternative beta-lactams (ceftriaxone or piperacillin), selected according to surgical site. Antibiotics were administered 1\u20132 hours before incision and continued for 3\u20135 days postoperatively, reflecting standards of care at the time.<\/p>\n Results.<\/strong> Ceftazidime showed efficacy comparable to ceftriaxone in uterine surgery and superior outcomes compared with piperacillin in biliary procedures. In gastric surgery, a lower incidence of postoperative sepsis was observed with ceftazidime. Conversely, in colorectal surgery, ceftazidime demonstrated reduced effectiveness, likely due to inadequate anaerobic coverage, now addressed by regimens combining a cephalosporin with metronidazole. No P. aeruginosa<\/em>-related respiratory infections occurred in patients receiving ceftazidime.<\/p>\n Conclusions.<\/strong> Ceftazidime is an effective prophylactic agent in selected abdominal surgeries, particularly where antipseudomonal coverage is relevant. Interpreted through contemporary guidelines, these findings highlight the need for site-specific, microbiology-informed prophylactic strategies that account for emerging patterns of antimicrobial resistance.<\/p>\n <\/p>\n","protected":false},"featured_media":5072,"template":"","meta":{"_acf_changed":false},"schedule":[5],"speaker-category":[6],"class_list":["post-5200","speaker","type-speaker","status-publish","has-post-thumbnail","hentry","schedule-day-1","speaker-category-speakers"],"acf":[],"yoast_head":"\n